Skip to Main Content

Paper Details

Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.
Lancet Oncol
2
2021
Author NameAffiliation
Ronald de WitErasmus University Medical Center
  • 1 - 1

Datasets

Release 1.2